Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) was upgraded by research analysts at Vetr from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday. The brokerage currently has a $6.64 price objective on the biotechnology company’s stock. Vetr‘s price target would indicate a potential upside of 5.06% from the company’s current price.

A number of other research analysts also recently commented on the stock. HC Wainwright decreased their price objective on shares of Aurinia Pharmaceuticals from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday, May 18th. Zacks Investment Research downgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, June 27th. BidaskClub downgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Finally, Cantor Fitzgerald set a $14.00 target price on shares of Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 11th. One investment analyst has rated the stock with a sell rating and nine have issued a buy rating to the company’s stock. Aurinia Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $9.71.

Aurinia Pharmaceuticals (NASDAQ AUPH) opened at 6.32 on Wednesday. The company’s market cap is $527.63 million. Aurinia Pharmaceuticals has a 12-month low of $2.00 and a 12-month high of $10.54. The stock’s 50 day moving average is $6.22 and its 200 day moving average is $6.64.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.10. Aurinia Pharmaceuticals had a negative net margin of 16,648.93% and a negative return on equity of 28.61%. The company had revenue of $0.33 million during the quarter, compared to the consensus estimate of $0.06 million. On average, equities analysts forecast that Aurinia Pharmaceuticals will post ($0.94) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Aurinia Pharmaceuticals Inc (AUPH) Rating Increased to Buy at Vetr Inc.” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.dailypolitical.com/2017/09/15/aurinia-pharmaceuticals-inc-auph-rating-increased-to-buy-at-vetr-inc.html.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. FMR LLC lifted its stake in shares of Aurinia Pharmaceuticals by 0.3% during the 2nd quarter. FMR LLC now owns 5,867,800 shares of the biotechnology company’s stock worth $35,969,000 after buying an additional 19,200 shares during the last quarter. NEA Management Company LLC lifted its stake in shares of Aurinia Pharmaceuticals by 18.2% during the 1st quarter. NEA Management Company LLC now owns 4,808,483 shares of the biotechnology company’s stock worth $35,294,000 after buying an additional 740,740 shares during the last quarter. Vivo Capital LLC lifted its stake in shares of Aurinia Pharmaceuticals by 68.9% during the 2nd quarter. Vivo Capital LLC now owns 1,013,149 shares of the biotechnology company’s stock worth $6,211,000 after buying an additional 413,149 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Aurinia Pharmaceuticals by 357.3% during the 2nd quarter. Goldman Sachs Group Inc. now owns 876,461 shares of the biotechnology company’s stock worth $5,373,000 after buying an additional 684,816 shares during the last quarter. Finally, Balyasny Asset Management LLC lifted its stake in shares of Aurinia Pharmaceuticals by 66.7% during the 2nd quarter. Balyasny Asset Management LLC now owns 500,000 shares of the biotechnology company’s stock worth $3,065,000 after buying an additional 200,000 shares during the last quarter. Institutional investors own 27.83% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.